NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 150 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 150 is a fixed-dose oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works by inhibiting aromatic amino acid decarboxylation, allowing more levodopa to reach the brain while reducing peripheral side effects. The entacapone component extends levodopa's duration of action by inhibiting catechol-O-methyltransferase.
$0.127MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D spending ($127K); brand team likely focused on managed decline or transition planning.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 150 offers exposure to mature-market brand management, managed-care negotiations, and generic transition planning—valuable skills but limited growth runway. This role suits professionals seeking stable portfolio stewardship or transition expertise rather than high-growth product launches.
Brand Manager
Worked on STALEVO 150 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.